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(GC) are interchangeable; however, the molecular differ-
ences driving tumorigenesis for these cancers remain poorly
defined. The present study utilized biomarker analysis of
actionable targets for IHC and GC to distinguish them and
potentially refine current treatment strategies.
217 IHC and 28 GC specimens referred to Caris Life Sci-
ences between 2009 thru 2012 were evaluated. Specific
testing by immunohistochemical analysis for 17 different
biomarkers was performed. In the collective cohort
(n = 245), actionable targets included: 95% low TS, 82% low
RMM1, and 74% low ERCC1, indicating potential suscep-
tibility to fluoropyrimidines/capecitabine, gemcitabine, and
platinum agents, respectively. Additional non-NCCN com-
pendium targets included TOPO1 (53.3% high, irinotecan),
MGMT (50.3% low, temozolomide), TOP2A (33% high,
anthracyclines), and PGP (30.1% low, taxanes). Subgroup
analysis by tumor origin demonstrated a differential
biomarker expression pattern with a higher frequency of IHC
tumors showing low levels of TS (99% vs. 72%, p < 0.0001),
and RRM1 (85% vs. 64%, p = 0.021) when compared to GC.
Conversely a greater frequency of GC demonstrated high
levels of TOPO1 (76% vs. 50%, p = 0.018) versus IHC,
indicating a potential increased benefit from irinotecan.
Biomarker analysis possesses the capacity to identify addi-
tional targets for which established agents are available. Dif-
ferences in molecular profiles of IHC and GC provide
evidence that the two are distinct diseases and require differ-
ent treatments.
FRIDAY, MARCH 13, 2015,
12:30PM–1:00PM
LUNCH VIDEO PRESENTATION
VL.01 TRANS-THORACIC MINIMALLY
INVASIVE SEGMENT 8 LIVER
RESECTION GUIDED BY AUGMENTED
REALITY
J. Hallet1,2,4, L. Soler1,2, M. Diana2, D. Mutter1,2,3,
T. Baumert2, F. Habersetzer2, J. Marescaux1,2, P. Pessaux1,2,3
1Institut De Recherche Sur Les Cancers De L’Appareil
Digestif (IRCAD), Strasbourg, ALSACE; 2Institut
Hospitalier Universitaire De Strasbourg, Universitaire
Strasbourg, Strasbourg, ALSACE; 3Service De Chirurgie
Digestive, Nouvel Hal Civil, Strasbourg, ALSACE;
4Sunnybrook Health Sciences Centre – Odette Cancer
Centre, Toronto, ONTARIO
Background: Liver dome tumors are not traditionally ame-
nable to minimally invasive hepatectomy (MIH) due to
superior/central location. In order to increase the number of
lesions amenable to MIH, new approaches are needed. Addi-
tional challenges in MIH include loss of 3D visualization and
tactile perception for intraoperative guidance within the
intra-hepatic anatomy.
Methods: This video includes the use of a pre-operative 3D
virtual model and intra-operative augmented reality (AR)
navigation to facilitate trans-thoracic MIH of the liver
dome.
Results: We present a 52 year-old gentleman with a 3 cm
isolated hepatocellular carcinoma in segment 8. A trans-
thoracic approach was chosen to allow for MIH. The video
begins with presentation of 3D reconstruction and virtual
resection planning. Principles of AR are detailed. The surgi-
cal steps include positioning and triangulation of thoracic
ports under AR guidance, followed by trans-diaphragmatic
tumor localization, identification of the phrenotomy site, and
planning of margins using intra-operative ultrasound com-
bined with AR. The parenchyma is transected with bipolar
radiofrequency ablation and ultrasonic scalpel. After closure
of diaphragm, the specimen is extracted through an enlarged
thoracic port, and a chest tube is placed. The procedure was
well tolerated. The chest tube was pulled on day 3 and dis-
charge occurred on day 4.
Conclusion: This video of liver resection for challenging
tumor localization illustrates a different, safe, and valuable
approach to MIH. It highlights how 3D virtual resection
planning and AR can enhance and facilitate complex MIH,
thereby easing the transition into the minimally invasive era
for liver surgery.
FRIDAY, MARCH 13, 2015,
3:00PM–4:30PM
LONG ORAL A –
PANCREAS ONCOLOGY
LO-A.01 UTILITY OF ESTABLISHING
A PANCREAS CANCER SCREENING
PROGRAM WITHIN A HIGH VOLUME
PANCREATIC CANCER PROGRAM
B. A. Krzywda, S. M. Lahiff, D. M. McDowell, B. George,
P. S. Ritch, B. A. Erickson, F. M. Johnston,
K. K. Christians, D. B. Evans, S. Tsai
Medical College Of Wisconsin, Milwaukee, WI
Background: Approximately 10% of pancreatic cancer
(PC) may be hereditary and screening of high risk individuals
has been recommended. Herein we describe the establish-
ment of a comprehensive multidisciplinary screening
program.
Methods: Screening criteria included the presence of PC
in: 2+ first-degree relatives (FDR), or 3+ any degree relatives
(ADR), or any known hereditary cancer syndrome with
increased PC risk. Lifetime PC risk was calculated using the
CancerGene PancPro software. The clinic provided genetic
counseling and nutrition/wellness education. MRI imaging
was selectively recommended based the lifetime PC risk.
Results: Forty-three patients were screened; 65% were
female and the median age was 54 (IQR:11). Family history
was significant for two FDR in 12 (28%) patients and three
ADR in 11 (26%). Median age of the earliest affected family
member with PC was 59 (IQR:15). Hereditary cancer syn-
dromes were present in 18 (41%) patients: BRCA1(3),
BRCA2(6), MLH1(1), PMS2(1), PALB2(1), ATM(1),
CDKN2A(4) and STK11(1). Median PancPro estimated life-
time risk of screened patients was 7% (IQR:6). Twenty-two
(51%) of 43 patients had a lifetime risk over 10%. Elevated
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